Drug Profile
Research programme: dementia therapeutics - Pacific Northwest Biotechnology
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pacific Northwest Biotechnology
- Class
- Mechanism of Action Matrix metalloproteinase inhibitors; Proto-oncogene protein c-met stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dementia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dementia in USA
- 03 Dec 2007 Preclinical trials in Dementia in USA (unspecified route)